ClinicalTrials.gg
Enrolling by invitationNCT01460264BIG3Updated Aug 29, 2025

An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study

An observational study in Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases and Lung Cancer, sponsored by Region Skane. Enrolling by invitation at 1 site in Sweden. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Region Skane · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden — 16 open to participants now, 24 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sweden.

Planned enrollment
6th of 28
10,000 · median 470
Started
2013
with 7 others
Observational
29 of 152
4 open now
Primary completion
2026-12
later than 8 of 23 live
Registered
49th of 152
by date

Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, this one is the 6th largest by planned enrollment of the 28 observational ones that give a count, is one of 8 that started in 2013, is one of 29 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 49th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

16 of the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, or all of them as a file.
02

Study summary

This is an observational study aiming to identify and validate biomarkers (including imaging and clinical descriptors) for chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD) and lung cancer.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Cardiovascular Diseases
  • Lung Cancer

Keywords

  • Prospective Cohort Study
  • Respiratory Function Tests
  • Computed Tomography
  • Electrocardiography
  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Community sample,residents in Skåne county Sweden.

Eligibility criteria

Inclusion Criteria:

  • 45-75 years
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • exposed

    current daily smokers 100 cigarettes or more during lifetime

  • unexposed

    current non-smokers

06

Study locations

1 site
07

References and documents

Publications

  • Gerhardsson de Verdier M. The big three concept: a way to tackle the health care crisis? Proc Am Thorac Soc. 2008 Dec 1;5(8):800-5. doi: 10.1513/pats.200806-058TH. PubMed 19017732 ↗
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2013 (actual). Primary completion is estimated for Dec 2026, 158 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 158 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2011
First posted
Oct 26, 2011
StartActual
Oct 16, 2013
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01460264
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Oct 26, 2011
Start date
Oct 16, 2013
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 29, 2025

Study contacts

Louise Hagman Bennet, MD, PhD
study chair · Skane University Hospital
David Erlinge, MD, PhD
principal investigator · Skane University Hospital
Claes-Göran Löfdahl, MD, PhD
principal investigator · Skane University Hospital
Maria Planck, MD, PhD
principal investigator · Skane University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion